Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + liposomal doxorubicin + dexamethasone + bortezomib
- Development stage
- Phase 3
- Lead developer
- Beijing Chaoyang Hospital
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
CDD + bortezomib is an investigational combination chemotherapy regimen consisting of cyclophosphamide, liposomal doxorubicin, dexamethasone (collectively known as CDD), and the proteasome inhibitor bortezomib. This regimen is primarily being evaluated in Phase 3 clinical trials sponsored by Beijing Chao Yang Hospital for the treatment of patients with relapsed or refractory multiple myeloma who have developed extramedullary plasmacytoma (EMP). The combination utilizes a multi-targeted approach: bortezomib disrupts protein homeostasis by inhibiting the 26S proteasome; cyclophosphamide acts as a DNA alkylating agent; liposomal doxorubicin inhibits DNA topoisomerase II and intercalates DNA; and dexamethasone acts as a glucocorticoid receptor agonist to induce apoptosis in malignant plasma cells. This synergistic combination is designed to overcome treatment resistance and target malignant cells both within the bone marrow and in extramedullary sites.
- Other names
- CDD Plus BortezomibCyclophosphamide, Liposome Doxorubicin, Dexamethasone Plus Bortezomib
02
Targets
DNAGR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + liposomal doxorubicin + dexamethasone + bortezomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + liposomal doxorubicin + dexamethasone + bortezomib.